Results 261 to 270 of about 89,492 (311)

Modeling Polymeric Drug Release: The Emerging Role of Machine Learning. [PDF]

Wiley Interdiscip Rev Nanomed Nanobiotechnol
Woodring RN, Ainslie KM.
europepmc   +1 more source

PLGA nanoparticles in otoprotection and inner ear regeneration: a new frontier in nanomedicine for hearing disorders. [PDF]

RSC Adv
Jimoh OO, Ajuwon T, Okonkwo SS, Awoyemi RF, Olaosebikan I, Olahanmi OA, Mbonu C, Junaid IO, Odezuligbo I, Olotu K, Ifijen IH.   +10 more
europepmc   +1 more source

PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances. [PDF]

Pharmaceutics
Stevanović MM, Qian K, Huang L, Vukomanović M.   +3 more
europepmc   +1 more source

Decidualization-empowered ECM hydrogel integrating sustained Tβ4 release drives endometrial regeneration in intrauterine adhesions. [PDF]

Nat Commun
Liang Y, Yu Z, Du S, Guo Y, Li J, Yan Y, Jin S, Liang W, Li M, Jin N, Yang J, Peng Z, Chen Z, Yang H, Liu Z, Shuai Q, Li L, Xie J.   +17 more
europepmc   +1 more source

Hepatocyte-Targeted Epicatechin Nanoparticles Promote Autophagy and Enhance Mitochondrial Function in Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Int J Nanomedicine
Han D, Lee H, Lee S, Lee K, Lee NK, Jin TE, Lee J, Kim JS, Kim DK, Shin J, Park HW.   +10 more
europepmc   +1 more source

PLGA Spherical Nucleic Acids

Advanced Materials, 2018
AbstractA new class of polymer spherical nucleic acid (SNA) conjugates comprised of poly(lactic‐co‐glycolic acid) (PLGA) nanoparticle (NP) cores is reported. The nucleic acid shell that defines the PLGA‐SNA exhibits a half‐life of more than 2 h in fetal bovine serum.
Hang Xing, Chad A Mirkin
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Platelet Compatibility of PLGA, Chitosan and PLGA–Chitosan Nanoparticles

Nanomedicine, 2009
The increasing interest in biodegradable nanoparticles containing biomaterials such as poly(D,L-lactide-co-glycolide) (PLGA) and chitosan for drug delivery raises issues regarding the blood compatibility of these nanoparticles, since some nanoparticles, including carbon nanoparticles, can affect human platelet aggregation and cause vascular thrombosis.
Xue, Li, Anna, Radomski, Owen I, Corrigan, Lidia, Tajber, Fabio, De Sousa Menezes, Sibylle, Endter, Carlos, Medina, Marek W, Radomski   +7 more
openaire   +2 more sources

Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation

Journal of Controlled Release, 2019
Injectable, long-acting depot formulations based on poly(lactide-co-glycolide) (PLGA) have been used clinically since 1989. Despite 30 years of development, however, there are only 19 different drugs in PLGA formulations approved by the U.S. Food and Drug Administration (FDA). The difficulty in developing depot formulations stems in large part from the
Kinam Park, Sarah Skidmore, Andrew Otte
exaly   +3 more sources

PLGA Microspheres Encapsulating siRNA

2014
The therapeutic use of small interfering RNA (siRNA) represents a new and powerful approach to suppress the expression of pathologically genes. However, biopharmaceutical drawbacks, such as short half-life, poor cellular uptake, and unspecific distribution into the body, hamper the development of siRNA-based therapeutics.
DE ROSA, GIUSEPPE, SALZANO, GIUSEPPINA
openaire   +3 more sources